Investigational drug · Phase 2
HS-20118
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Moderate to Severe Plaque Psoriasis.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "HS-20118"
First trial start
2026
Aug 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-20118", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-20118" as an intervention, largest first.
- Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118Pivotal-lookingRecruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07033234 · 142 participants (planned) · Start May 16, 2025 · Primary completion Mar 2026
Drug: HS-20118 · For: Psoriasis
Sites: Hangzhou, China
- A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque PsoriasisPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07765628 · 120 participants (planned) · Start Aug 6, 2026 · Primary completion Feb 28, 2027
Drug: HS-20118; Placebo · For: Moderate to Severe Plaque Psoriasis
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06846710 · 60 participants · Start May 2, 2025 · Primary completion Jul 14, 2026
Drug: HS-20118 · For: Psoriasis
Sites: Anaheim, California; Miami Lakes, Florida; Pompano Beach, Florida · 9 sites in all
- A Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy ParticipantsActive, not recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07896915 · 32 participants · Start Aug 3, 2026 · Primary completion Dec 25, 2026
Drug: HS-20118; HS-20118 · For: Healthy Participants
Sites: Haikou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Moderate to Severe Plaque Psoriasis
- CMS-D001Phase 32 trials
Dermavon Holdings Limited · Moderate to Severe Plaque Psoriasis, Moderate to Severe Atopic Dermatitis
- SYHX1901Phase 32 trials
CSPC Ouyi Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata
- WD-890Phase 32 trials
Zhejiang Wenda Pharma Technology LTD. · Brief Description of Focus of Study, Moderate to Severe Plaque Psoriasis
- SHR-1139Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.